EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

A review of the safety of sodium‐glucose co‐transporter‐2 inhibitors

Daniel Vincent O'Hara iD, Meg J Jardine

Diabetes, Obesity and Metabolism · 2025-07 · 27 (7) · 3598-3606

DOI: 10.1111/dom.16385 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 08.04.2025. Verfasst von Daniel Vincent O'Hara und 1 weiteren Autor:innen. Beteiligte Einrichtung: NHMRC Clinical Trials Centre, Faculty of Health and Medicine, University of Sydney, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Hypoglycemic Agents. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The development of sodium‐glucose co‐transporter‐2 (SGLT2) inhibitors represents a major turning point in the effort to preserve kidney function and prevent cardiovascular events and heart failure hospitalisations in those at high risk. These agents have now transcended their original glucose‐lowering indication and provide a range of clinical benefits in people both with and without diabetes, and at varying levels of kidney function. Despite this, SGLT2 inhibitors remain underutilized by the medical community. One potential barrier to improved uptake may be concern about adverse effects. The following review summarizes the wealth of information garnered from clinical trials and real‐world data in recent years to examine the safety of SGLT2 inhibitors and to provide practical advice to promote safer use of these important therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsDiabetes Mellitus, Type 2Hypoglycemic AgentsHumansCardiovascular Diseases

Stichwörter der Autor:innen

SGLT2 inhibitorattitudesbarriersreal‐world evidence

Substanzen

Sodium-Glucose Transporter 2 InhibitorsHypoglycemic Agents

Autor:innen und Institutionen

  • NHMRC Clinical Trials Centre, Faculty of Health and Medicine, University of Sydney, Sydney, New South Wales, Australia.
  • Royal North Shore Hospital Renal Department, Sydney, New South Wales, Australia.
  • Concord Repatriation General Hospital, Sydney, New South Wales, Australia.

ORCID-Profile: Daniel Vincent O'Hara

Zitieren

APA

O'Hara, D. V., & Jardine, M. J. (2025). A review of the safety of sodium‐glucose co‐transporter‐2 inhibitors. Diabetes, Obesity and Metabolism, 27(7), 3598-3606. https://doi.org/10.1111/dom.16385

Vancouver

O'Hara DV, Jardine MJ. A review of the safety of sodium‐glucose co‐transporter‐2 inhibitors. Diabetes, Obesity and Metabolism. 2025;27(7):3598-3606. doi:10.1111/dom.16385

BibTeX
@article{OHara2025,
  author = {O'Hara, Daniel Vincent and Jardine, Meg J},
  title = {A review of the safety of sodium‐glucose co‐transporter‐2 inhibitors},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2025},
  volume = {27},
  number = {7},
  pages = {3598--3606},
  doi = {10.1111/dom.16385}
}
Kostenlos starten →